Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials.

[Guest guest]

J Med Virol. 2011 May;83(5):815-9. doi: 10.1002/jmv.22049.

Efficacy of interferon-based antiviral therapy in patients with chronic

hepatitis C infected with genotype 5: A meta-analysis of two large prospective

clinical trials.

D'Heygere F, C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M,

Delwaide J, Laureys A, Nevens F.

AZ Groeninge Hospital, Kortrijk, Belgium.

Abstract

The characteristics and response rate to pegylated interferon and ribavirin

(PEG-INF + RBV) of patients with chronic hepatitis C infected with genotype

5 are poorly documented. A meta-analysis of two large phase III/IV prospective

randomized clinical trials conducted in Belgium in patients with chronic

hepatitis C (n = 1,073 patients) was performed in order to compare the

response to antiviral therapy of hepatitis C virus (HCV) genotype 5 with that of

other HCV genotypes. A subset of HCV-1 infected patients selected from within

the study database were selected to match the HCV-5 sample for known prognostic

factors. In Belgium HCV-5 is responsible for a significant minority of cases of

chronic hepatitis C CHC (4.5%) and is characterized by a more advanced age (58.4

years), a high frequency of cirrhosis (27.7%), a specific mode of HCV

acquisition, and a particular geographic origin (66.7% of patients from West

Flanders). The primary comparative analysis showed that response to treatment

with PEG-INF + RBV of HCV-5 is similar to HCV-1 and lower compared to

HCV-2/3. The analysis of the matched patient subgroup demonstrates that the

HCV-5 " intrinsic sensitivity " to PEG-IFN + RBV therapy is identical to

HCV-1, with a sustained virological response of 55% in both groups. In contrast

to previous publications, this meta-analysis suggests that HCV-5 response to

treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5

infection should be treated with the same antiviral regimen as HCV-1. J. Med.

Virol. 83:815-819, 2011. © 2011 Wiley-Liss, Inc.

Copyright © 2011 Wiley-Liss, Inc.

PMID: 21412790 [PubMed - in process]

[Guest guest]

J Med Virol. 2011 May;83(5):815-9. doi: 10.1002/jmv.22049.

Efficacy of interferon-based antiviral therapy in patients with chronic

hepatitis C infected with genotype 5: A meta-analysis of two large prospective

clinical trials.

D'Heygere F, C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M,

Delwaide J, Laureys A, Nevens F.

AZ Groeninge Hospital, Kortrijk, Belgium.

Abstract

The characteristics and response rate to pegylated interferon and ribavirin

(PEG-INF + RBV) of patients with chronic hepatitis C infected with genotype

5 are poorly documented. A meta-analysis of two large phase III/IV prospective

randomized clinical trials conducted in Belgium in patients with chronic

hepatitis C (n = 1,073 patients) was performed in order to compare the

response to antiviral therapy of hepatitis C virus (HCV) genotype 5 with that of

other HCV genotypes. A subset of HCV-1 infected patients selected from within

the study database were selected to match the HCV-5 sample for known prognostic

factors. In Belgium HCV-5 is responsible for a significant minority of cases of

chronic hepatitis C CHC (4.5%) and is characterized by a more advanced age (58.4

years), a high frequency of cirrhosis (27.7%), a specific mode of HCV

acquisition, and a particular geographic origin (66.7% of patients from West

Flanders). The primary comparative analysis showed that response to treatment

with PEG-INF + RBV of HCV-5 is similar to HCV-1 and lower compared to

HCV-2/3. The analysis of the matched patient subgroup demonstrates that the

HCV-5 " intrinsic sensitivity " to PEG-IFN + RBV therapy is identical to

HCV-1, with a sustained virological response of 55% in both groups. In contrast

to previous publications, this meta-analysis suggests that HCV-5 response to

treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5

infection should be treated with the same antiviral regimen as HCV-1. J. Med.

Virol. 83:815-819, 2011. © 2011 Wiley-Liss, Inc.

Copyright © 2011 Wiley-Liss, Inc.

PMID: 21412790 [PubMed - in process]